Core Insights - Apellis is focused on the complement pathways, particularly complement factor C3, which allows exploration of various therapeutic options across multiple areas [1] - The company is currently self-funded and has identified growth drivers for both the near and long term [2] Company Overview - Apellis has established a foundation around its products SYFOVRE and EMPAVELI, which are expected to support its future pipeline [2] - SYFOVRE is generating a steady and durable revenue stream that aligns with the company's long-term growth ambitions [2]

Summary of Apellis Pharmaceuticals FY Conference Call Company Overview - **Company**: Apellis Pharmaceuticals (NasdaqGS:APLS) - **Focus**: Complement pathways, specifically complement factor C3, with therapeutic options across various areas [2][3] Key Products and Market Position Syfovre - **Market Leadership**: Holds approximately 60% market share in geographic atrophy [4] - **Revenue Growth**: Achieved 17% year-over-year growth in total injections [4] - **Future Growth Drivers**: Anticipates renewed growth in 2027 with the introduction of a prefilled syringe, enhancing ease of administration [3][8] - **Patient Segmentation**: Targets advanced geographic atrophy, wet macular degeneration, and early geographic atrophy patients [5][6] - **Clinical Evidence**: Largest dataset in geographic atrophy shows the ability to slow disease progression by 1.5 years over five years [8][9] Empaveli - **Indications**: Approved for C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis (IC-MPGN) [4][14] - **Market Penetration**: Achieved over 5% penetration in the first full quarter post-launch, with expectations of reaching approximately half of the 5,000 patient population [16] - **Launch Success**: Described as one of the best launches in rare disease nephrology, with strong payer reception [17][14] - **Clinical Trials**: Ongoing phase III trials for focal segmental glomerulosclerosis (FSGS) and delayed graft function, potentially expanding access to an additional 30,000 patients [14][19] Pipeline Developments - **APL-3007 Program**: A subcutaneous injection aimed at reducing systemic C3 levels by approximately 90%, potentially allowing for less frequent injections [13] - **Gene-Editing Approach**: APL-9099 program targeting the $20 billion FCRN market with a focus on reducing IgG levels while maintaining albumin levels [20][21] Market Dynamics and Competitive Landscape - **Competitive Advantage**: The prefilled syringe for Syfovre is expected to improve treatment flow in retina practices, enhancing competitive positioning against Izervae [8][28] - **Market Stability**: Syfovre's market share has remained stable, with a slight decrease in new patient share (50%-55%) compared to overall market share [41][42] - **Urgency in Nephrology**: Emphasized the need for improved patient identification and education among nephrologists to drive treatment urgency for Empaveli [17][38] Challenges and Considerations - **Regulatory Hurdles**: Syfovre has not yet received EMA approval, with ongoing efforts to address concerns regarding measuring functional benefits [31][33] - **Patient Access Issues**: Previous disruptions in treatment flow due to financial barriers have been addressed, leading to improved patient care dynamics [25][27] Conclusion - **Outlook**: Apellis Pharmaceuticals is positioned for growth with a strong pipeline and market leadership in geographic atrophy and nephrology, while navigating regulatory challenges and enhancing patient access strategies [22][42]